A group of investors led by Vatera Healthcare Partners has added $69 million to Pearl Therapeutics’s funding, bringing the total to more than $102 million since 2007. Pearl’s lead candidate, PT003, a glycopyrrolate/formoterol MDI for the treatment of COPD is in Phase 2B studies, and Pearl plans to begin Phase 3 trials by the end of 2012. Vatera was founded by Michael Jaharis, a co-founder of Kos Pharmaceuticals. Read the company’s press release.
Pearl raises $69 million
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA